Navigation Links
Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March
Date:3/7/2012

SAN DIEGO, March  7, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the following two investor conferences in March:

  • 24th Annual Roth Conference in Dana Point on March 14, 2012 at 12:30 p.m. ET/9:30 a.m. PT. Kurt Gustafson, Chief Financial Officer of Halozyme Therapeutics, will provide a corporate overview.
  • Barclays Capital 2012 Global Healthcare Conference in Miami on March 14, 2012 at 4:15 p.m. ET/1:15 p.m. PT. Gregory I. Frost, Ph.D., President and Chief Executive Officer of Halozyme Therapeutics, will provide a corporate overview.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The presentations will be webcast through the "Investors" section of Halozyme's corporate website at www.halozyme.com, and recordings will be made available for 90 days following the events. To access the live webcasts, please log on to Halozyme's website approximately fifteen minutes prior to the presentations to register and download any necessary audio software.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headqua
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Halozyme to Host Fourth Quarter and 2011 Year-End Financial Results Conference Call
2. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
3. Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
4. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
5. Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
6. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
7. Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions
8. Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
9. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
10. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
11. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... The Regulatory Affairs Professionals Society ... offices in Asia—one in Singapore and one in Shanghai, ... RAPS’ Pan-Asia office , serving the Asia Pacific region, ... audiences within China. , The announcement comes just a ... Singapore government agencies to develop and implement a new ...
(Date:6/18/2013)... DuPont welcomes 48 of the nation’s finest agricultural ... Teachers Ambassador Academy this week (NATAA) at the company’s ... , The NATAA “Ag Academy” is a professional development ... of the National FFA Foundation and the ... The highly recommended agriscience teachers, who are participating in ...
(Date:6/18/2013)... 2013 The Pistoia Alliance ... HELM biomolecular representation standard software toolkit and editor ... HELM (Hierarchical Editing Language for Macromolecules) enables ... (e.g. proteins, nucleotides, antibody drug conjugates) whose size ... methodologies impractical or unusable. HELM solves this problem ...
(Date:6/18/2013)...  AMRI (NASDAQ: AMRI ) announced ... , site has received approval to expand its ... handle Schedule 2 and 2N controlled substances. The ... Burlington,s physical security and quality systems, ... http://photos.prnewswire.com/prnh/20120229/NY61160LOGO ) With its ...
Breaking Biology Technology:RAPS Opens Offices in Singapore and China 2RAPS Opens Offices in Singapore and China 3DuPont Sponsors National AgriScience Ambassador Academy 2DuPont Sponsors National AgriScience Ambassador Academy 3The Pistoia Alliance Releases HELM Biomolecular Representation Standard Open Source Tools 2AMRI Burlington Receives DEA Approval to Handle Controlled Substances 2
... September 1, 2010 ... ... var shortURL ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result = ...
... Deloitte Recap recently presented the Allicense 2010 ... biotechnology firm, Exelixis, in recognition of their potential ... worldwide exclusive licenses for two early-stage cancer treatments ... inhibitor programs.  In exchange, Sanofi-aventis provided Exelixis an ...
... Rx, the developers of PharmFilm® technology and a ... today announced that its partner, Reckitt Benckiser Pharmaceuticals ... plc (LSE: RB), has received approval from the ... Suboxone® (buprenorphine HCl/naloxone HCl dihydrate) sublingual film for ...
Cached Biology Technology:Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 2Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 3Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 4Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 5Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 6Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 7Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 8Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 9Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 10Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 11Deloitte Recap Honors Sanofi-aventis and Exelixis With the Allicense 2010 Breakthrough Alliance Award for Early-Stage Collaboration in Cancer 2MonoSol Rx Announces Reckitt Benckiser FDA Approval of Suboxone® Sublingual Film for Treatment of Opioid Dependence 2MonoSol Rx Announces Reckitt Benckiser FDA Approval of Suboxone® Sublingual Film for Treatment of Opioid Dependence 3
(Date:6/17/2013)... 2013 An international team led by scientists at ... Institute and Albert Einstein College of Medicine of Yeshiva ... that attacks the tuberculosis (TB) bacterium in two different ... solve one of the major global health crises of ... strains," said Peter G. Schultz, the Scripps Family Chair ...
(Date:6/17/2013)... ST. LOUIS -- In research published in Biochemical ... describe a technology that can detect new, previously unknown ... for viruses even when doctors have not identified a ... , In the new approach, scientists use ... discover viruses. , Taking advantage of the complete deciphering ...
(Date:6/17/2013)... early onset of puberty in girls, a new clinical ... Endocrine Society,s 95th Annual Meeting in San Francisco. , ... 10 and 14. Boys undergo these changes later, usually ... is diagnosed in girls when sexual development begins before ... when these changes occur before age 9. , Recently, ...
Breaking Biology News(10 mins):New compound excels at killing persistent and drug-resistant tuberculosis 2New compound excels at killing persistent and drug-resistant tuberculosis 3New compound excels at killing persistent and drug-resistant tuberculosis 4Saint Louis University researchers discover a way to detect new viruses 2Saint Louis University researchers discover a way to detect new viruses 3Vitamin D supplementation may delay precocious puberty in girls 2
... to examine the role of sweeteners in the ... among various ingredients used in scientific studies, ,according ... distinctly different ingredients, such ,as pure fructose and ... and misleads ,consumers. Recent studies using ...
... Ben-Gurion University of the Negev engineers have developed ... reactors, making it unsuitable for use in nuclear arms. ... the basic synthetic element found in commercial smoke detectors ... peaceful purposes. , This technique could help "de-claw" more ...
... similar, if not lower, costs and very large reductions ... one of the key take-home messages from a series ... America,s Energy Future (RBAEF)" in a special issue of ... journal believes that the collection, which includes a comparative ...
Cached Biology News:Pure fructose frequently confused with high fructose corn syrup 2Ben-Gurion University engineers develop technique to help combat nuclear proliferation 2Cellulosic biofuel technology will generate low-cost green fuel, says major study 2Cellulosic biofuel technology will generate low-cost green fuel, says major study 3
Plasmid expressing Zeocin resistance gene....
...
Hygromycin resistance gene (hph), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
... template is designed to allow neomycin/kanamycin ... The FRT-PGK-gb2-neo-FRT template encodes the neomycin/kanamycin resistance ... for expression of kanamycin resistance in ... for expression of neomycin resistance in mammalian ...
Biology Products: